Robert N Goldstone1, Shirin R Hasan2, Steven Drury3, Teresa M Darragh4, Annemieke van Zante5, Stephen E Goldstone6. 1. Massachusetts General Hospital, Boston, MA, USA. 2. Medtronic, Sunnyvale, CA, USA. 3. Medtronic, New Haven, CT, USA. 4. Departments of Pathology and Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA. 5. Department of Pathology, University of California San Francisco, San Francisco, CA, USA. 6. Icahn School of Medicine, Mount Sinai, 420 West 23rd St, New York, NY, 10011, USA. goldstone.stephen@gmail.com.
Abstract
PURPOSE: Radiofrequency ablation (RFA) effectively treats esophageal high-grade dysplasia, but its efficacy in treating anal canal high-grade squamous intraepithelial lesions (HSILs) is unsubstantiated. This prospective study assessed the safety and efficacy of applying hemi-circumferential RFA to anal canal HSIL. METHODS: Twenty-one HIV-negative participants with HSIL occupying ≤ half the anal canal circumference were treated with hemi-circumferential anal canal RFA. Participants were assessed every 3 months for 12 months with high-resolution anoscopy; recurrence in the treatment zone was re-treated with focal RFA. RESULTS: Twenty-one participants with a mean of 1.7 lesions (range 1-4) enrolled and completed the trial. Six (29 %) participants had recurrent HSIL within the treated hemi-circumference within 1 year. Four participants (19 %) had persistence of an index lesion at 3 months. One (2.9 %) index HSIL persisted again at 12 months. No participants had more than two RFA treatments. KM curve-predicted HSIL-free survival within the treatment zone at 1 year was 76 % (95 % CI 52-89 %). Comparing the first 7 and last 14 participants, the predicted 1-year HSIL-free survivals are 43 % (95 % CI 10-73 %) and 93 % (95 % CI 59-99 %), respectively (p = 0.008), suggesting a learning curve with the treating physician. Multivariable analysis showed decreased recurrence in the last 14 participants (HR 0.02; 95 % CI 0.001-0.63) while increasing BMI increased recurrence (HR 1.43, 95 % CI 1.01-2.01). No participants had device or procedure-related serious adverse events, anal stricture, or heavy bleeding. CONCLUSIONS: Hemi-circumferential RFA yielded a high rate of anal HSIL eradication in HIV-negative patients at 1 year with minimal adverse events. Lesion persistence was probably related to incomplete initial ablation.
PURPOSE: Radiofrequency ablation (RFA) effectively treats esophageal high-grade dysplasia, but its efficacy in treating anal canal high-grade squamous intraepithelial lesions (HSILs) is unsubstantiated. This prospective study assessed the safety and efficacy of applying hemi-circumferential RFA to anal canal HSIL. METHODS: Twenty-one HIV-negative participants with HSIL occupying ≤ half the anal canal circumference were treated with hemi-circumferential anal canal RFA. Participants were assessed every 3 months for 12 months with high-resolution anoscopy; recurrence in the treatment zone was re-treated with focal RFA. RESULTS: Twenty-one participants with a mean of 1.7 lesions (range 1-4) enrolled and completed the trial. Six (29 %) participants had recurrent HSIL within the treated hemi-circumference within 1 year. Four participants (19 %) had persistence of an index lesion at 3 months. One (2.9 %) index HSIL persisted again at 12 months. No participants had more than two RFA treatments. KM curve-predicted HSIL-free survival within the treatment zone at 1 year was 76 % (95 % CI 52-89 %). Comparing the first 7 and last 14 participants, the predicted 1-year HSIL-free survivals are 43 % (95 % CI 10-73 %) and 93 % (95 % CI 59-99 %), respectively (p = 0.008), suggesting a learning curve with the treating physician. Multivariable analysis showed decreased recurrence in the last 14 participants (HR 0.02; 95 % CI 0.001-0.63) while increasing BMI increased recurrence (HR 1.43, 95 % CI 1.01-2.01). No participants had device or procedure-related serious adverse events, anal stricture, or heavy bleeding. CONCLUSIONS: Hemi-circumferential RFA yielded a high rate of anal HSIL eradication in HIV-negative patients at 1 year with minimal adverse events. Lesion persistence was probably related to incomplete initial ablation.
Authors: K K Wang; J M Tian; E Gorospe; J Penfield; G Prasad; T Goddard; M Wongkeesong; N S Buttar; L Lutzke; S Krishnadath Journal: Dis Esophagus Date: 2012-03-12 Impact factor: 3.429
Authors: Khaled A Hamdan; Iain S Tait; Valerie Nadeau; Miles Padgett; Frank Carey; Robert J Steele Journal: Dis Colon Rectum Date: 2003-11 Impact factor: 4.585
Authors: John A Evans; Dayna S Early; Norio Fukami; Tamir Ben-Menachem; Vinay Chandrasekhara; Krishnavel V Chathadi; G Anton Decker; Robert D Fanelli; Deborah A Fisher; Kimberly Q Foley; Joo Ha Hwang; Rajeev Jain; Terry L Jue; Khalid M Khan; Jenifer Lightdale; Phyllis M Malpas; John T Maple; Shabana F Pasha; John R Saltzman; Ravi N Sharaf; Amandeep Shergill; Jason A Dominitz; Brooks D Cash Journal: Gastrointest Endosc Date: 2012-12 Impact factor: 9.427
Authors: K Nadine Phoa; Roos E Pouw; Frederike G I van Vilsteren; Carine M T Sondermeijer; Fiebo J W Ten Kate; Mike Visser; Sybren L Meijer; Mark I van Berge Henegouwen; Bas L A M Weusten; Erik J Schoon; Rosalie C Mallant-Hent; Jacques J G H M Bergman Journal: Gastroenterology Date: 2013-03-28 Impact factor: 22.682
Authors: Pascal Gervaz; Dieter Hahnloser; Bruce G Wolff; Sarah A Anderson; Julie Cunningham; Robert W Beart; Adam Klipfel; Lawrence Burgart; Stephen N Thibodeau Journal: J Gastrointest Surg Date: 2004-12 Impact factor: 3.452
Authors: Elizabeth A Stier; Stephen E Goldstone; J Michael Berry; Lori A Panther; Naomi Jay; Susan E Krown; Jeannette Lee; Joel M Palefsky Journal: J Acquir Immune Defic Syndr Date: 2008-01-01 Impact factor: 3.731
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Jack E Burkhalter; Thomas M Atkinson; J Berry-Lawhorn; Stephen Goldstone; Mark H Einstein; Timothy J Wilkin; Jeannette Lee; David Cella; Joel M Palefsky Journal: Value Health Date: 2018-04-11 Impact factor: 5.725